Stocktoria
Laboratorios Farmaceuticos Rovi, S.A. ROVI.MC
ES · Bolsa de Madrid · XMAD · stock · Healthcare · website
Laboratorios Farmaceuticos Rovi, S.A. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | €743.5M | €763.7M | €829.5M | €817.7M |
| Gross profit | €482.7M | €478.3M | €492.3M | €519.6M |
| SG&A expense | €36.0M | €39.4M | €38.0M | €32.8M |
| Operating income | €185.8M | €179.5M | €220.3M | €255.8M |
| Interest expense | €2.6M | €2.0M | €667,000 | €606,000 |
| Income tax | €42.9M | €40.8M | €50.1M | €58.3M |
| Net income | €140.4M | €136.9M | €170.3M | €199.7M |
| EPS (diluted) | €2.75 | €2.68 | €3.29 | €3.73 |
| Operating cash flow | €187.1M | €138.3M | €113.2M | €237.6M |
| Free cash flow | €119.3M | €76.1M | €58.1M | €186.2M |
| Cash & equivalents | €98.0M | €27.2M | €25.3M | €124.9M |
| Inventory | €288.0M | €330.0M | €338.0M | €311.9M |
| Goodwill | €2.7M | €0 | — | — |
| Total assets | €955.7M | €832.0M | €799.9M | €878.7M |
| Total debt | €121.7M | €114.4M | €65.4M | €72.1M |
| Total liabilities | €280.2M | €250.5M | €256.4M | €357.3M |
| Shareholders' equity | €664.4M | €572.0M | €539.4M | €520.0M |
| Share buybacks | €54.9M | €89.7M | €133.9M | €177.0M |
Growth · year-over-year · Revenue CAGR -3.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -2.7% | -7.9% | +1.4% | — |
| Net income growth | +2.6% | -19.6% | -14.7% | — |
| EPS growth | +2.8% | -18.6% | -11.9% | — |
| Free cash flow growth | +56.8% | +31.0% | -68.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · ES · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.